Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides

Emilia D'Elia, Attilio Iacovoni, Muthiah Vaduganathan, Ferdinando L. Lorini, Stefano Perlini, Michele Senni

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

The autonomic nervous system, the renin–angiotensin–aldosterone system, and the natriuretic peptide system represent critical regulatory pathways in heart failure and as such have been the major targets of pharmacological development. The introduction and approval of angiotensin receptor neprilysin inhibitors (ARNi) have broadened the available drug treatments of patients with chronic heart failure with reduced ejection fraction. Neprilysin catalyses the degradation of a number of vasodilator peptides, including the natriuretic peptides, bradykinin, substance P, and adrenomedullin, as well as vasoconstrictor peptides, including endothelin-1 and angiotensin I and II. We review the multiple, potentially competing, substrates for neprilysin inhibition, and the resultant composite clinical effects of ARNi therapy. A mechanistic understanding of this novel therapeutic class may provide important insights into the expected on-target and off-target effects when this agent is more widely prescribed.

Original languageEnglish
Pages (from-to)710-717
Number of pages8
JournalEuropean Journal of Heart Failure
Volume19
Issue number6
DOIs
Publication statusPublished - Jun 1 2017

Fingerprint

Neprilysin
Natriuretic Peptides
Heart Failure
Angiotensin Receptors
Adrenomedullin
Angiotensin I
Peptides
Critical Pathways
Autonomic Nervous System
Bradykinin
Vasoconstrictor Agents
Endothelin-1
Substance P
Vasodilator Agents
Angiotensin II
Therapeutics
Pharmacology
Pharmaceutical Preparations

Keywords

  • Biomarkers
  • Heart failure
  • Neprilysin
  • Neurohormonal activation
  • Pharmacology

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Neprilysin inhibition in heart failure : mechanisms and substrates beyond modulating natriuretic peptides. / D'Elia, Emilia; Iacovoni, Attilio; Vaduganathan, Muthiah; Lorini, Ferdinando L.; Perlini, Stefano; Senni, Michele.

In: European Journal of Heart Failure, Vol. 19, No. 6, 01.06.2017, p. 710-717.

Research output: Contribution to journalReview article

D'Elia, Emilia ; Iacovoni, Attilio ; Vaduganathan, Muthiah ; Lorini, Ferdinando L. ; Perlini, Stefano ; Senni, Michele. / Neprilysin inhibition in heart failure : mechanisms and substrates beyond modulating natriuretic peptides. In: European Journal of Heart Failure. 2017 ; Vol. 19, No. 6. pp. 710-717.
@article{fc5b9df3113047cfaa3ccc59a5b9d8b0,
title = "Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides",
abstract = "The autonomic nervous system, the renin–angiotensin–aldosterone system, and the natriuretic peptide system represent critical regulatory pathways in heart failure and as such have been the major targets of pharmacological development. The introduction and approval of angiotensin receptor neprilysin inhibitors (ARNi) have broadened the available drug treatments of patients with chronic heart failure with reduced ejection fraction. Neprilysin catalyses the degradation of a number of vasodilator peptides, including the natriuretic peptides, bradykinin, substance P, and adrenomedullin, as well as vasoconstrictor peptides, including endothelin-1 and angiotensin I and II. We review the multiple, potentially competing, substrates for neprilysin inhibition, and the resultant composite clinical effects of ARNi therapy. A mechanistic understanding of this novel therapeutic class may provide important insights into the expected on-target and off-target effects when this agent is more widely prescribed.",
keywords = "Biomarkers, Heart failure, Neprilysin, Neurohormonal activation, Pharmacology",
author = "Emilia D'Elia and Attilio Iacovoni and Muthiah Vaduganathan and Lorini, {Ferdinando L.} and Stefano Perlini and Michele Senni",
year = "2017",
month = "6",
day = "1",
doi = "10.1002/ejhf.799",
language = "English",
volume = "19",
pages = "710--717",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "John Wiley & Sons, Ltd",
number = "6",

}

TY - JOUR

T1 - Neprilysin inhibition in heart failure

T2 - mechanisms and substrates beyond modulating natriuretic peptides

AU - D'Elia, Emilia

AU - Iacovoni, Attilio

AU - Vaduganathan, Muthiah

AU - Lorini, Ferdinando L.

AU - Perlini, Stefano

AU - Senni, Michele

PY - 2017/6/1

Y1 - 2017/6/1

N2 - The autonomic nervous system, the renin–angiotensin–aldosterone system, and the natriuretic peptide system represent critical regulatory pathways in heart failure and as such have been the major targets of pharmacological development. The introduction and approval of angiotensin receptor neprilysin inhibitors (ARNi) have broadened the available drug treatments of patients with chronic heart failure with reduced ejection fraction. Neprilysin catalyses the degradation of a number of vasodilator peptides, including the natriuretic peptides, bradykinin, substance P, and adrenomedullin, as well as vasoconstrictor peptides, including endothelin-1 and angiotensin I and II. We review the multiple, potentially competing, substrates for neprilysin inhibition, and the resultant composite clinical effects of ARNi therapy. A mechanistic understanding of this novel therapeutic class may provide important insights into the expected on-target and off-target effects when this agent is more widely prescribed.

AB - The autonomic nervous system, the renin–angiotensin–aldosterone system, and the natriuretic peptide system represent critical regulatory pathways in heart failure and as such have been the major targets of pharmacological development. The introduction and approval of angiotensin receptor neprilysin inhibitors (ARNi) have broadened the available drug treatments of patients with chronic heart failure with reduced ejection fraction. Neprilysin catalyses the degradation of a number of vasodilator peptides, including the natriuretic peptides, bradykinin, substance P, and adrenomedullin, as well as vasoconstrictor peptides, including endothelin-1 and angiotensin I and II. We review the multiple, potentially competing, substrates for neprilysin inhibition, and the resultant composite clinical effects of ARNi therapy. A mechanistic understanding of this novel therapeutic class may provide important insights into the expected on-target and off-target effects when this agent is more widely prescribed.

KW - Biomarkers

KW - Heart failure

KW - Neprilysin

KW - Neurohormonal activation

KW - Pharmacology

UR - http://www.scopus.com/inward/record.url?scp=85016274480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016274480&partnerID=8YFLogxK

U2 - 10.1002/ejhf.799

DO - 10.1002/ejhf.799

M3 - Review article

AN - SCOPUS:85016274480

VL - 19

SP - 710

EP - 717

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 6

ER -